Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease
20/5 13:29
(RTTNews) - Viridian Therapeutics Inc. (VRDN) announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug or "veli", an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye...